Murdaca G, Colombo B M, Puppo F
Department of Internal Medicine, University of Genova, Genova, Italy.
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):557-65. doi: 10.1177/039463200902200301.
The ongoing progresses in the knowledge of the pathogenic mechanisms of various inflammatory or immune-mediated diseases and the availability of innovative biotechnological approaches have lead to the development of new drugs which add to conventional treatments. TNF-alpha inhibitors (infliximab, adalimumab and etanercept) have demonstrated efficacy either as monotherapy or in combination with other anti-inflammatory or disease modifying anti-rheumatic drugs (DMARDs). The efficacy and safety profile of the TNF-alpha inhibitors can be considered, in general, as a class effect. Nevertheless, some differences may exist among the three agents. In this paper, we will briefly review the indications for the use of the three TNF-alpha inhibitors, the pre-treatment considerations and the reported adverse events.
在各种炎症或免疫介导疾病的致病机制知识方面的不断进展以及创新生物技术方法的可用性，已促成了新药物的开发，这些新药物补充了传统治疗方法。肿瘤坏死因子-α抑制剂（英夫利昔单抗、阿达木单抗和依那西普）已证明无论是作为单一疗法还是与其他抗炎或改善病情抗风湿药物（DMARDs）联合使用均有效。一般而言，肿瘤坏死因子-α抑制剂的疗效和安全性概况可被视为一种类效应。然而，这三种药物之间可能存在一些差异。在本文中，我们将简要回顾三种肿瘤坏死因子-α抑制剂的使用指征、治疗前注意事项以及报告的不良事件。
